Wave Life Sciences (WVE) Scheduled to Post Quarterly Earnings on Tuesday

Wave Life Sciences (NASDAQ:WVE - Get Free Report) will be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Wave Life Sciences to post earnings of ($0.28) per share for the quarter.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.09). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 1,395.99%. The company had revenue of $19.69 million during the quarter, compared to analyst estimates of $24.80 million. During the same period in the prior year, the business earned ($0.20) EPS. On average, analysts expect Wave Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Wave Life Sciences Stock Up 0.4 %

Wave Life Sciences stock traded up $0.05 during midday trading on Tuesday, hitting $13.84. 1,002,557 shares of the stock were exchanged, compared to its average volume of 1,099,906. The stock has a market capitalization of $1.73 billion, a PE ratio of -24.28 and a beta of -1.20. Wave Life Sciences has a 52 week low of $3.50 and a 52 week high of $15.92. The company has a fifty day simple moving average of $9.20 and a two-hundred day simple moving average of $6.97.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on WVE. B. Riley raised their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock a "buy" rating in a research note on Monday. JPMorgan Chase & Co. boosted their target price on Wave Life Sciences from $13.00 to $17.00 and gave the stock an "overweight" rating in a report on Thursday, October 17th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of Wave Life Sciences in a research report on Thursday, October 31st. Raymond James raised shares of Wave Life Sciences from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the company from $13.00 to $22.00 in a report on Wednesday, October 16th. Finally, Leerink Partners boosted their price target on Wave Life Sciences from $20.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, October 16th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Wave Life Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $19.78.

Insider Buying and Selling

In related news, insider Chris Francis sold 208,836 shares of the firm's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $13.67, for a total transaction of $2,854,788.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Paul Bolno sold 48,366 shares of the firm's stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $5.78, for a total transaction of $279,555.48. Following the completion of the sale, the chief executive officer now directly owns 359,059 shares of the company's stock, valued at $2,075,361.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Chris Francis sold 208,836 shares of the business's stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $13.67, for a total transaction of $2,854,788.12. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 364,822 shares of company stock worth $4,645,768. 29.10% of the stock is owned by corporate insiders.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.